Downregulation of TRPC6 regulates ERK1/2 to prevent sublytic C5b‑9 complement complex‑induced podocyte injury through activating autophagy

IF 2.4 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Yuanyuan Li, Youfu Fang, Jing Liu
{"title":"Downregulation of TRPC6 regulates ERK1/2 to prevent sublytic C5b‑9 complement complex‑induced podocyte injury through activating autophagy","authors":"Yuanyuan Li, Youfu Fang, Jing Liu","doi":"10.3892/etm.2023.12275","DOIUrl":null,"url":null,"abstract":"Idiopathic membranous nephropathy (IMN) is a common glomerular disease, in which 50‑60% of patients can progress to end‑stage renal disease within 10‑20 years, seriously endangering human health. Podocyte injury is the direct cause of IMN. Sublytic C5b‑9 complement complex induces damage in podocytes' structure and function. In sublytic C5b‑9 treated podocytes, the expression of canonical transient receptor potential 6 (TRPC6) is increased. However, the specific mechanism of TRPC6 in sublytic C5b‑9 treated podocytes is unclear. The present study aimed to reveal the effect and mechanism of TRPC6 on sublytic C5b‑9‑induced podocytes. Normal human serum was stimulated using zymosan to form C5b‑9. A lactate dehydrogenase release assay was used to examine C5b‑9 cytotoxicity in podocytes. The RNA and protein expression levels were analyzed using reverse transcription‑quantitative PCR, western blotting and immunofluorescent assay, respectively. Cell Counting Kit‑8 assay and flow cytometry were carried out to test the viability and apoptosis of podocytes, respectively. Transmission electron microscopy was used to observe autophagic vacuole. F‑actin was tested through phalloidin staining. Sublytic C5b‑9 was deposited and TRPC6 expression was boosted in podocytes stimulated through zymosan activation serum. Knockdown of TRPC6 raised the viability and reduced the apoptosis rate of sublytic C5b‑9‑induced podocytes. Meanwhile, transfection of small‑interfering (si)TRPC6 facilitated autophagy progression and enhanced the activation of cathepsin B/L in sublytic C5b‑9‑induced podocytes. The phosphorylation level of ERK1/2 was receded in siTRPC6 and sublytic C5b‑9 co‑treated podocytes. Moreover, the addition of the ERK1/2 activator partially reversed the effect of TRPC6 inhibition on sublytic C5b‑9‑induced podocytes. TRPC6 knockdown reduced the damage of sublytic C5b‑9 to podocytes by weakening the ERK1/2 phosphorylation level to activate autophagy. These results indicated that targeting TRPC6 reduced the injury of sublytic C5b‑9 on podocytes.","PeriodicalId":12285,"journal":{"name":"Experimental and therapeutic medicine","volume":"563 1","pages":"0"},"PeriodicalIF":2.4000,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and therapeutic medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3892/etm.2023.12275","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Idiopathic membranous nephropathy (IMN) is a common glomerular disease, in which 50‑60% of patients can progress to end‑stage renal disease within 10‑20 years, seriously endangering human health. Podocyte injury is the direct cause of IMN. Sublytic C5b‑9 complement complex induces damage in podocytes' structure and function. In sublytic C5b‑9 treated podocytes, the expression of canonical transient receptor potential 6 (TRPC6) is increased. However, the specific mechanism of TRPC6 in sublytic C5b‑9 treated podocytes is unclear. The present study aimed to reveal the effect and mechanism of TRPC6 on sublytic C5b‑9‑induced podocytes. Normal human serum was stimulated using zymosan to form C5b‑9. A lactate dehydrogenase release assay was used to examine C5b‑9 cytotoxicity in podocytes. The RNA and protein expression levels were analyzed using reverse transcription‑quantitative PCR, western blotting and immunofluorescent assay, respectively. Cell Counting Kit‑8 assay and flow cytometry were carried out to test the viability and apoptosis of podocytes, respectively. Transmission electron microscopy was used to observe autophagic vacuole. F‑actin was tested through phalloidin staining. Sublytic C5b‑9 was deposited and TRPC6 expression was boosted in podocytes stimulated through zymosan activation serum. Knockdown of TRPC6 raised the viability and reduced the apoptosis rate of sublytic C5b‑9‑induced podocytes. Meanwhile, transfection of small‑interfering (si)TRPC6 facilitated autophagy progression and enhanced the activation of cathepsin B/L in sublytic C5b‑9‑induced podocytes. The phosphorylation level of ERK1/2 was receded in siTRPC6 and sublytic C5b‑9 co‑treated podocytes. Moreover, the addition of the ERK1/2 activator partially reversed the effect of TRPC6 inhibition on sublytic C5b‑9‑induced podocytes. TRPC6 knockdown reduced the damage of sublytic C5b‑9 to podocytes by weakening the ERK1/2 phosphorylation level to activate autophagy. These results indicated that targeting TRPC6 reduced the injury of sublytic C5b‑9 on podocytes.
下调TRPC6调控ERK1/2,通过激活自噬来防止亚溶性C5b - 9补体复合体诱导的足细胞损伤
特发性膜性肾病(Idiopathic membrane nephropathy, IMN)是一种常见的肾小球疾病,其中50 ~ 60%的患者可在10 ~ 20年内发展为终末期肾病,严重危害人类健康。足细胞损伤是IMN发生的直接原因。亚溶解C5b‑9补体复合体诱导足细胞结构和功能损伤。在亚溶C5b - 9处理的足细胞中,典型瞬时受体电位6 (TRPC6)的表达增加。然而,TRPC6在亚溶性C5b - 9处理足细胞中的具体机制尚不清楚。本研究旨在揭示TRPC6对亚溶解C5b - 9诱导足细胞的作用及其机制。使用酶生酶刺激正常人血清形成C5b - 9。乳酸脱氢酶释放法检测足细胞中C5b - 9的细胞毒性。分别用逆转录定量PCR、western blotting和免疫荧光法分析RNA和蛋白质的表达水平。采用细胞计数试剂盒- 8法和流式细胞术分别检测足细胞的活力和凋亡。透射电镜观察自噬液泡。通过phalloidin染色检测F - actin。在酶酶酶激活血清刺激的足细胞中,亚溶解的C5b - 9沉积,TRPC6表达增强。敲低TRPC6可提高亚溶性C5b - 9诱导足细胞的生存能力,降低其凋亡率。同时,转染小干扰(si)TRPC6促进了自噬的进展,并增强了亚溶解C5b - 9诱导足细胞中组织蛋白酶B/L的激活。在siTRPC6和亚溶解C5b - 9共处理的足细胞中,ERK1/2的磷酸化水平降低。此外,ERK1/2激活剂的加入部分逆转了TRPC6抑制对亚溶解C5b - 9诱导的足细胞的作用。TRPC6敲低通过削弱ERK1/2磷酸化水平激活自噬,降低亚溶解C5b - 9对足细胞的损伤。这些结果表明,靶向TRPC6可减少亚溶性C5b - 9对足细胞的损伤。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Experimental and therapeutic medicine
Experimental and therapeutic medicine MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
1.50
自引率
0.00%
发文量
570
审稿时长
1 months
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信